Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma

Replimune Group, Inc. (NASDAQ: REPL) has announced the commercial availability of TUDRIQEV™ (vusolimogene oderparepvec-wtpg) in the United States. This treatment is indicated for adult patients with unresectable advanced cutaneous melanoma who have shown disease progression after a PD-1-blocking antibody-based regimen, and it is used in combination with nivolumab.